Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENESIS: Motixafortide + G-CSF vs placebo + G-CSF for stem cell mobilization in multiple myeloma
2024-511953-23-00Phase 3Authorised
- Sponsor
- BioLineRx Ltd.
- Start
- Jul 2024
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Motixafortide + G-CSF with Placebo + G-CSF (2 arms). Planned start Jul 2024; status: authorised.
02
Drugs
motixafortide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511953-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511953-23-00.